D-dimer as an early marker of severity in patients with acute superior mesenteric venous thrombosis

Medicine (Baltimore). 2014 Dec;93(29):e270. doi: 10.1097/MD.0000000000000270.

Abstract

No early serum marker of disease severity contributes to the treatment decision-making process of acute superior mesenteric venous thrombosis (ASMVT). This study aims to assess the value of serum D-dimer level in the first 3 days after admission as a severity marker of ASMVT patients. From May 2010 to June 2014, 50 consecutive patients of ASMVT were enrolled in this observational study. The serum D-dimer level was measured on a daily basis during the first 3 days after admission as well as other laboratory-testing parameters, clinical score, and outcome variables recorded during the same period. The maximum and mean D-dimer values were analyzed and compared with other potential markers for prediction of multiple-organ dysfunction syndrome (MODS) and short-bowel syndrome (SBS). The correlation of D-dimer level with other potential severity markers and inflammation parameters were also studied. Both maximum and mean D-dimer level during the first 3 days of admission were significantly higher in patients with several clinical variables such as death within 30 days, bowel resection, sepsis, abdominal compartment syndrome, MODS, and SBS. In addition, serum D-dimer level showed precise prediction for MODS and SBS, greater than L-lactate and intestinal-type fatty acid-binding protein (I-FABP). The D-dimer level was correlated well with L-lactate, I-FABP, and APACHE II score on the first 3 days of admission. Poor correlation of D-dimer level and inflammation parameters, white blood cell count, and C-reactive protein level, was detected. D-dimer level could be an effective, early, and specific serum marker indicating the clinical evolution and outcome of ASMVT.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • APACHE
  • Adult
  • Biomarkers / blood
  • Early Diagnosis
  • Fatty Acid-Binding Proteins / blood
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis*
  • Humans
  • Lactic Acid / blood
  • Male
  • Mesenteric Ischemia / blood*
  • Mesenteric Ischemia / diagnosis*
  • Middle Aged
  • Multiple Organ Failure / blood
  • Multiple Organ Failure / diagnosis
  • Peptide Fragments / blood
  • Pilot Projects
  • Severity of Illness Index*
  • Short Bowel Syndrome / blood
  • Short Bowel Syndrome / diagnosis

Substances

  • Biomarkers
  • Fatty Acid-Binding Proteins
  • Fibrin Fibrinogen Degradation Products
  • Peptide Fragments
  • fibrin fragment D
  • intestinal fatty acid-binding protein (1-19), human
  • Lactic Acid